A RANDOMIZED TRIAL OF ARTESUNATE–SULFAMETHOXYPYRAZINE–PYRIMETHAMINE VERSUS ARTEMETHER–LUMEFANTRINE FOR THE TREATMENT OF UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA IN MALI
2006; American Society of Tropical Medicine and Hygiene; Volume: 75; Issue: 4 Linguagem: Inglês
10.4269/ajtmh.2006.75.630
ISSN1476-1645
AutoresIssaka Sagara, Alassane Dicko, Abdoulaye Djimdé, Ousmane Guindo, Mamady Kone, Youssouf Tolo, Mahamadou A. Théra, Moussa Sogoba, Mamady Fofana, Amed Ouattara, Mady Sissoko, Herwig Jansen, Ogobara K. Doumbo,
Tópico(s)Drug-Induced Hepatotoxicity and Protection
ResumoThe choice of artemisinin-based combination that is being adopted for malaria treatment in sub-Saharan Africa may depend on several factors, including cost, efficacy, side effects, and simplicity of administration. We tested the hypothesis that artesunate–sulfamethoxypyrazine–pyrimethamine is as efficacious as the four-dose regimen of artemether–lumefantrine for treatment of Plasmodium falciparum malaria. The study was carried out during two transmission seasons (2003 and 2004) in Sotuba, Mali. Participants at least 6 months of age with uncomplicated P. falciparum malaria were randomly assigned to receive artesunate–sulfamethoxypyrazine–pyrimethamine or artemether–lumefantrine. Treatment efficacy was assessed using the World Health Organization 28-day protocol. A total of 606 (303 in each arm) patients were enrolled. The cure rate was higher for artesunate–sulfamethoxypyrazine–pyrimethamine than for artemether–lumefantrine (98.7% versus 89.6%; P < 0.0001). After correction for cases of re-infection, the cure rates were 100% and 99.0%, respectively ( P = 0.08). No serious adverse events occurred. Artesunate–sulfamethoxypyrazine–pyrimethamine is well-tolerated and effective against P. falciparum malaria. It showed an additional benefit of preventing new infections.
Referência(s)